Abstract:Background: Influenza virus remains a continuous and severe threat to public health worldwide, and its prevention and treatment have always been a major international issue. Because of its ability to evade immune surveillance through rapid antigenic drift and antigenic shift, broad-spectrum vaccines seem increasingly important. Methods: A mAb named 3C12 from an immortalized hybrid cell was generated via immunizing mice with HA2 protein from A/chicken/Anhui/BRI99/2016 (AH/BRI99/16, H9N2) generated by prokaryotic expression. Then, its broad-spectrum activity was analyzed by WB and IFA. Next, the minimal linear epitope was identified via analyzing the reaction of a series of HA truncations with 3C12. Finally, the protective effects of 3C12 were evaluated in vitro and in vivo infection experiments. Results: The mAb could react with the viruses of subtypes H1, H2, H5, H8, H9, H12, H13, H16, and HA protein of H18 in group 1, but failed to react with viruses in group 2. The minimal linear epitope targeted by the mAb was 433NAELLVL439 in full length of HA and localized in the C-helix region of HA2 (residue 95-101, HA2 numbering). What's more, the mAb 3C12 inhibited H1, H2, H5, H8, H9, H12, H13 and H16 virus-replication in vitro and also has shown effectiveness in preventing and treating disease in mice challenged with lethal dose of AH/BRI99/16 (H9N2) virus in vivo. These results suggested that the broadly reactive anti-HA stem mAb 3C12 exhibited prophylactic and therapeutic efficacy. Conclusions: Here, we have demonstrated that the linear epitope identified in this study could be a novel target for developing broad-spectrum influenza diagnostics or vaccine design, and the HA2-based monoclonal antibody is indeed a promising strategy for broad-spectrum protection against seasonal and pandemic influenza viruses.

Generation, characterization, and protective ability of mouse monoclonal antibodies against the HA of A (H1N1) influenza virus

Generation and Characterization of Monoclonal Antibodies Against the Hemagglutinin of H3N2 Influenza A Viruses.

Evaluation of Panel of Neutralising Murine Monoclonal Antibodies and a Humanised Bispecific Antibody Against Influenza A(H1N1)pdm09 Virus Infection in a Mouse Model.

Preparation and characterization of mouse-derived monoclonal antibodies against the hemagglutinin of the H1N1 influenza virus

Generation of Neutralizing and Non-Neutralizing Monoclonal Antibodies Against H7N9 Influenza Virus.

Characterization of Monoclonal Antibodies Against Ha Protein of H1n1 Swine Influenza Virus and Protective Efficacy Against H1 Viruses in Mice

The generation of hemagglutinin monoclonal antibodies against H9N2 influenza virus

Identification of broad-spectrum neutralizing antibodies against influenza A virus and evaluation of their prophylactic efficacy in mice

Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection

Characterization of antibodies specific for hemagglutinin and neuraminidase proteins of the 1918 and 2009 pandemic H1N1 viruses.

Identification and Structural Characterization of a Broadly Neutralizing Antibody Targeting a Novel Conserved Epitope on the Influenza Virus H5N1 Hemagglutinin

A Cross-Reactive Monoclonal Antibody Against Neuraminidases of Both H9N2 and H3N2 Influenza Viruses Shows Protection in Mice Challenging Models

Identification and Analysis of B Cell Epitopes of Hemagglutinin of H1N1 Influenza Virus.

Humanized Antibodies with Broad-Spectrum Neutralization to Avian Influenza Virus H5N1.

Generation, Characterization and Epitope Mapping of Two Neutralizing and Protective Human Recombinant Antibodies Against Influenza A H5N1 Viruses.

Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes.

Monoclonal antibody specific to HA2 glycopeptide protects mice from H3N2 influenza virus infection

Generation of Human Neutralizing Monoclonal Antibodies Against the 2009 Pandemic H1N1 Virus from Peripheral Blood Memory B Lymphocytes.

Hemagglutinin stalk-based monoclonal antibody elicits broadly reactivity against group 1 influenza A virus

Generation and Preliminary Characterization of Monoclonal Antibodies Against Neuraminidase of H7N9 Subtype Influenza A Virus

Properties and Therapeutic Efficacy of Broadly Reactive Chimeric and Humanized H5-specific Monoclonal Antibodies Against H5N1 Influenza Viruses.